Claims for Patent: 6,114,603

Summary for Patent: 6,114,603

Title:	Genetic engineering of sugarbeet plants
Abstract:	Methods for the transformation of sugarbeet which include the use of cyclical regeneration of the target plant and particle bombardment. Such methods allow for genotype-independent transformation. These methods further allow for a stably transformed sugarbeet plant. Plants produced in accordance with these methods are provided as well.
Inventor(s):	Christou; Paul (Norwich, GB), Pelica; Fatima (Bowthorpe, GB)
Assignee:	John Innes Center (Norwich, GB)
Application Number:	09/049,142
Patent Claims:	1. A method of making a genetically transformed sugarbeet plant comprising: preparing a transgene; attaching the transgene to a substantially biologically inert carrier particle to form at least one coated particle; producing at least one cyclically regenerated sugarbeet shoot via excising at least one embryo from at least one sugarbeet seed, culturing the at least one embryo, culturing a shoot apex which grows in culture from the at least one embryo, culturing a first plant tissue growth which grows in culture from the shoot apex, and culturing a second plant tissue growth which grows from the first plant tissue growth to obtain a cyclically regenerated sugarbeet shoot; forcing the at least one coated particle into the at least one cyclically regenerated sugarbeet shoot to obtain a transformed sugarbeet shoot; and regenerating a sugarbeet plant from said transformed shoot. 2. The method of claim 1, wherein the transgene comprises at least one expression construct. 3. The method of claim 2, wherein the expression construct comprises at least one coding sequence and at least one regulatory sequence. 4. The method of claim 3, wherein the at least one regulatory sequence comprises at least one promoter. 5. The method of claim 4, wherein the at least one promoter comprises a member selected from the group consisting of cauliflower mosaic virus 35s promoter with intron from maize alcohol dehydrogenase gene, cauliflower mosaic virus 35s promoter, cauliflower mosaic virus 35s promoter with alfalfa mosaic virus leader, and nopaline synthase promoter from Agrobacterium tumefaciens. 6. The method of claim 3, wherein the at least one regulatory sequence comprises a terminating signal. 7. The method of claim 6, wherein the terminating signal comprises a member selected from the group consisting of nopaline synthase polyadenylation signal from Agrobacterium tumefaciens, and soybean polyadenylation signal. 8. The method of claim 3, wherein the at least one coding sequence comprises at least one marker gene. 9. The method of claim 8, wherein the at least one marker gene comprises a selectable gene. 10. The method of claim 9, wherein the selectable gene comprises a member selected from the group consisting of bialaphos resistance gene, aminoglycoside-3-phosphotransferase II gene, and aminoglycoside phosphotransferase IV gene. 11. The method of claim 10, wherein the selectable gene comprises a bialaphos resistance gene. 12. The method of claim 11, wherein presence of the bialaphos resistance gene is verified by assay. 13. The method of claim 8, wherein the at least one marker gene comprises a detectable gene. 14. The method of claim 13, wherein the detectable gene comprises a member selected from the group consisting of luciferase gene, jellyfish green fluorescent protein gene, and .beta.-D-glucuronidase gene. 15. The method of claim 14, wherein the detectable gene comprises .beta.-D-glucuronidase gene. 16. The method of claim 15, wherein presence of the .beta.-D-glucuronidase gene is verified by assay. 17. The method of claim 8, wherein the at least one marker gene comprises at least one selectable gene and at least one detectable gene. 18. The method of claim 8, wherein the at least one marker gene comprises at least two selectable genes. 19. The method of claim 8, wherein the at least one marker gene comprises at least two detectable genes. 20. The method of claim 1, wherein the method comprises genotype-independent transformation. 21. The method of claim 1, wherein the carrier particles comprise metal. 22. The method of claim 21, wherein the metal comprises a member selected from the group consisting of gold, tungsten, iridium, ruthenium, rhodium, platinum, and palladium, and mixtures thereof. 23. The method of claim 1, comprising regenerating in RV medium. 24. The method of claim 23, comprising regenerating in MS medium. 25. The method of claim 1, wherein the shoots comprise sugarbeet cells at differing stages of the cell cycle. 26. A progeny population of a transgenic sugarbeet plant species comprising a stably integrated transgene in the progeny genome, wherein the transgene was stably integrated into the parent genome in the process comprising a cyclic regeneration system and particle bombardment of claim 1. 27. A sugarbeet plant as claimed in claim 26, wherein the progeny was propagated via self-pollination. 28. A sugarbeet cell in a cyclically regenerated sugarbeet plant comprising an inert metal particle coated with exogenous genetic material, said plant produced by the process of claim 1. 29. A sugarbeet plant comprising cyclically-regenerated plant tissue and a substantially biologically inert carrier particle and a transgene, said plant produced by the process of claim 1. 30. A sugarbeet plant comprising (a) a substantially biologically inert carrier particle, and (b) a transgene, and (c) a germline cell comprising the transgene stably integrated into the genome of said germline cell, said plant produced by the process of claim 1. 31. The sugarbeet plant of claim 30 wherein the sugarbeet plant comprises Beta vulgaris L. Var. Saccharifera (Altissima), a biennial plant of the genus Beta L., family Chenopodiaceae.

Details for Patent 6,114,603

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26